{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:02:32Z","timestamp":1791997352825,"version":"4.4.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"vor","delay-in-days":64,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"NIDA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience Applied"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.nsa.2024.104053","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T03:57:22Z","timestamp":1709697442000},"page":"104053","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A novel, non-opioid, selective orexin-1 receptor antagonist for the treatment of substance use disorders"],"prefix":"10.1016","volume":"3","author":[{"given":"Clare M.","family":"Murray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8786-1922","authenticated-orcid":false,"given":"J. Craig","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8937-003X","authenticated-orcid":false,"given":"Christian","family":"Heidbreder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nsa.2024.104053_bib1","series-title":"Provisional Drug Overdose Death Counts. National Center for Health Statistics","author":"Ahmad","year":"2023"},{"key":"10.1016\/j.nsa.2024.104053_bib2","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.peptides.2006.11.002","article-title":"The selective orexin 1 receptor antagonist SB-334867-A impairs acquisition and consolidation but not retrieval of spatial memory in Morris water maze","volume":"28","author":"Akbari","year":"2007","journal-title":"Peptides"},{"key":"10.1016\/j.nsa.2024.104053_bib3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.alcohol.2020.06.003","article-title":"Adolescent alcohol exposure increases orexin-A\/hypocretin-1 in the anterior hypothalamus","volume":"88","author":"Amodeo","year":"2020","journal-title":"Alcohol"},{"key":"10.1016\/j.nsa.2024.104053_bib4","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1292\/jvms.09-0397","article-title":"Changes in the gene expression and enzyme activity of hepatic cytochrome P450 in juvenile sprague-dawley rats","volume":"72","author":"Asaoka","year":"2010","journal-title":"J. Vet. Med. Sci."},{"key":"10.1016\/j.nsa.2024.104053_bib5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.neulet.2010.07.050","article-title":"Antagonism of orexin type 1 receptors in the locus coeruleus attenuates signs of naloxone-precipitated morphine withdrawal in rats","volume":"482","author":"Azizi","year":"2010","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.nsa.2024.104053_bib6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.24095\/hpcdp.42.2.01","article-title":"Patterns and motivations of polysubstance use: a rapid review of the qualitative evidence","volume":"42","author":"Boileau-Falardeau","year":"2022","journal-title":"Health Promotion and Chronic Disease Prevention in Canada"},{"key":"10.1016\/j.nsa.2024.104053_bib7","article-title":"Evaluation of JNJ-54717793 a novel brain penetrant selective orexin 1 receptor antagonist in 2 rat models of panic attach provocation","volume":"357","author":"Bonaventure","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.nsa.2024.104053_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph192416759","article-title":"Polysubstance use patterns among outpatients undergoing substance use disorder treatment: a latent class analysis","volume":"19","author":"Bonfiglio","year":"2022","journal-title":"Int. J. Environ. Res. Publ. Health"},{"key":"10.1016\/j.nsa.2024.104053_bib9","doi-asserted-by":"crossref","first-page":"19168","DOI":"10.1073\/pnas.0507480102","article-title":"Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior","volume":"102","author":"Boutrel","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.nsa.2024.104053_bib10","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.bbr.2015.05.051","article-title":"Hypocretin receptor 1 blockade preferentially reduces high effort responding for cocaine without promoting sleep","volume":"291","author":"Brodnik","year":"2015","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.nsa.2024.104053_bib11","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0028-3908(86)90058-4","article-title":"The effects of yohimbine on exploratory and locomotor behaviour are attributable to its effects at noradrenaline and not at benzodiazepine receptors","volume":"25","author":"Chopin","year":"1986","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.nsa.2024.104053_bib12","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1146\/annurev-pharmtox-010716-104837","article-title":"The discovery of suvorexant, the first orexin receptor drug for insomnia","volume":"57","author":"Coleman","year":"2017","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.nsa.2024.104053_bib13","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1073\/pnas.95.1.322","article-title":"The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity","volume":"95","author":"de Lecea","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.nsa.2024.104053_bib14","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1124\/jpet.109.152009","article-title":"Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat","volume":"330","author":"Dugovic","year":"2009","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.nsa.2024.104053_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2012.07.007","article-title":"Functional and binding kinetic studies make a distinction between OX1 and OX2 orexin receptor antagonists","volume":"692","author":"Faedo","year":"2012","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.nsa.2024.104053_bib17","doi-asserted-by":"crossref","DOI":"10.1111\/adb.12946","article-title":"Intermittent self- administration of fentanyl induces a multifaceted addiction state associated with persistent changes in the orexin system","volume":"26","author":"Fragale","year":"2021","journal-title":"Addiction Biol."},{"key":"10.1016\/j.nsa.2024.104053_bib16","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1038\/s41386-019-0420-x","article-title":"The role of orexin-1 receptor signaling in demand for the opioid fentanyl","volume":"44","author":"Fragale","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.nsa.2024.104053_bib18","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000118601","article-title":"Behavioral effects of yohimbine and chlordiazepoxide: dependence on the rat's previous familiarization with the test conditions","volume":"22","author":"Gentsch","year":"1989","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.nsa.2024.104053_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0016406","article-title":"Functional Magnetic Resonance Imaging reveals different neural substrates for the effects of orexin-1 and orexin-2 receptor antagonists","volume":"6","author":"Gozzi","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.nsa.2024.104053_bib20","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ynstr.2018.08.003","article-title":"Anti-stress neuropharmacological mechanisms and targets for addiction treatment: a translational framework","volume":"9","author":"Greenwald","year":"2018","journal-title":"Neurobiol. Stress."},{"key":"10.1016\/j.nsa.2024.104053_bib21","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nature04071","article-title":"A role for lateral hypothalamic orexin neurons in reward seeking","volume":"437","author":"Harris","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.nsa.2024.104053_bib22","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1177\/0269881116647506","article-title":"Lisdexamfetamine reduces the compulsive and perseverative behaviour of binge-eating rats in a novel food reward\/punished responding conflict model","volume":"30","author":"Heal","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.nsa.2024.104053_bib23","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/npp.2011.303","article-title":"The 5-HT2C receptor agonist lorcaserin reduces nicotine self-administration, discrimination, and reinstatement: relationship to feeding behavior and impulse control","volume":"35","author":"Higgins","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.nsa.2024.104053_bib24","doi-asserted-by":"crossref","first-page":"19480","DOI":"10.1073\/pnas.0808023105","article-title":"Insular hypocretin transmission regulates nicotine reward","volume":"105","author":"Hollander","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.nsa.2024.104053_bib25","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3389\/fnbeh.2012.00047","article-title":"Hypocretin- 1 receptors regulate the reinforcing and reward-enhancing effects of cocaine: pharmacological and behavioral genetics evidence","volume":"6","author":"Hollander","year":"2012","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.nsa.2024.104053_bib26","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.neulet.2016.10.051","article-title":"Intra-LC microinjection of orexin type-1 receptor antagonist SB-334867 attenuates the expression of glutamate-induced opiate withdrawal like signs during the active phase in rats","volume":"636","author":"Hooshmand","year":"2017","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.nsa.2024.104053_bib27","year":"2003"},{"key":"10.1016\/j.nsa.2024.104053_bib28","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/FBP.0b013e328343d761","article-title":"Orexin-1 receptor antagonist SB-334867 reduces the acquisition and expression of cocaine-conditioned reinforcement and the expression of amphetamine-conditioned reward","volume":"22","author":"Hutcheson","year":"2011","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.nsa.2024.104053_bib29","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/BF00401402","article-title":"Comprehensive Observational Assessment: ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the rat","volume":"13","author":"Irwin","year":"1968","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.nsa.2024.104053_bib30","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.biopsych.2018.07.022","article-title":"Increased number and activity of a lateral subpopulation of hypothalamic orexin\/hypocretin neurons underlies the expression of an addicted state in rats","volume":"85","author":"James","year":"2019","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.nsa.2024.104053_bib31","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.biopsych.2022.06.027","article-title":"Orexin reserve: a mechanistic framework for the role of orexins (hypocretins) in addiction","volume":"92","author":"James","year":"2022","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.nsa.2024.104053_bib32","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nm.2075","article-title":"A key role for orexin in panic anxiety","volume":"16","author":"Johnson","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.nsa.2024.104053_bib33","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.brainres.2011.03.045","article-title":"The orexin-1 receptor antagonist SB-334867 dissociates the motivational properties of alcohol and sucrose in rats","volume":"1391","author":"Jupp","year":"2011","journal-title":"Brain Res."},{"key":"10.1016\/j.nsa.2024.104053_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2020.110166","article-title":"Multiple-dose clinical pharmacology of the selective orexin-1 receptor antagonist ACT-539313","volume":"108","author":"Kaufmann","year":"2021","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.nsa.2024.104053_bib35","series-title":"Comparison of the Reinstatement of Cocaine-Seeking in Remission Induced by Cues, Drug or a Drug\/cue Combination \u2013 an IVSA Study in Rats","author":"Keogh","year":"2018"},{"key":"10.1016\/j.nsa.2024.104053_bib36","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/bph.12324","article-title":"Orexin\/hypocretin receptor signalling cascades","volume":"171","author":"Kukkonen","year":"2014","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.nsa.2024.104053_bib37","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/sj.bjp.0705610","article-title":"Characterisation of the binding of [3H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor","volume":"141","author":"Langmead","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.nsa.2024.104053_bib38","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/sj.bjp.0706789","article-title":"The orexin system regulates alcohol-seeking in rats","volume":"148","author":"Lawrence","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.nsa.2024.104053_bib39","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.neuropharm.2016.08.008","article-title":"Orexin-1 receptor blockade suppresses compulsive-like alcohol drinking in mice","volume":"110","author":"Lei","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.nsa.2024.104053_bib40","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/B978-0-444-59489-1.00007-0","article-title":"Multiple roles for orexin\/hypocretin in addiction","volume":"198","author":"Mahler","year":"2012","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.nsa.2024.104053_bib41","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1111\/j.1476-5381.2009.00127.x","article-title":"Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX2 receptor: EMPA: a selective antagonist of the OX2 receptor","volume":"156","author":"Malherbe","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.nsa.2024.104053_bib42","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/cne.1190","article-title":"Differential expression of orexin receptors 1 and 2 in the rat brain","volume":"435","author":"Marcus","year":"2001","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.nsa.2024.104053_bib43","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s40265-022-01699-y","article-title":"Daridorexant: first approval","volume":"82","author":"Markham","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.nsa.2024.104053_bib44","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/WNR.0000000000000120","article-title":"Blockade of hypocretin receptor-1 preferentially prevents cocaine seeking: comparison with natural reward seeking","volume":"25","author":"Martin-Fardon","year":"2014","journal-title":"Neuroreport"},{"key":"10.1016\/j.nsa.2024.104053_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fnint.2020.599710","article-title":"Blockade of orexin receptors in the posterior paraventricular nucleus of the thalamus prevents stress-induced reinstatement of reward-seeking behavior in rats with a history of ethanol dependence","volume":"14","author":"Matzeu","year":"2020","journal-title":"Front. Integr. Neurosci."},{"key":"10.1016\/j.nsa.2024.104053_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107906","article-title":"Targeting the orexin system for prescription opioid use disorder: orexin-1 receptor blockade prevents oxycodone taking and seeking in rats","volume":"164","author":"Matzeu","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.nsa.2024.104053_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fnbeh.2021.620868","article-title":"Cocaine-seeking behavior induced by orexin A administration in the posterior paraventricular nucleus of the thalamus is not long-lasting: neuroadaptation of the orexin system during cocaine abstinence","volume":"15","author":"Matzeu","year":"2021","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.nsa.2024.104053_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fnbeh.2021.787595","article-title":"Understanding the role of orexin neuropeptides in drug addiction: preclinical studies and translational value","volume":"15","author":"Matzeu","year":"2022","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.nsa.2024.104053_bib49","doi-asserted-by":"crossref","first-page":"9831","DOI":"10.1523\/JNEUROSCI.0255-19.2019","article-title":"Orexin-1 receptor signaling in ventral pallidum regulates motivation for the opioid remifentanil","volume":"39","author":"Mohammadkhani","year":"2019","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nsa.2024.104053_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2019.146461","article-title":"Persistent effects of the orexin-1 receptor antagonist SB-334867 on motivation for the fast acting opioid remifentanil","volume":"1731","author":"Mohammadkhani","year":"2020","journal-title":"Brain Res."},{"key":"10.1016\/j.nsa.2024.104053_bib51","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.alcohol.2009.07.002","article-title":"Orexin-1 receptor antagonism decreases ethanol consumption and preference selectively in high-ethanol\u2013preferring Sprague\u2013Dawley rats","volume":"43","author":"Moorman","year":"2009","journal-title":"Alcohol"},{"key":"10.1016\/j.nsa.2024.104053_bib52","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.brainres.2016.10.018","article-title":"Orexin\/hypocretin-1 receptor antagonism reduces ethanol self-administration and reinstatement selectively in highly motivated rats","volume":"1654","author":"Moorman","year":"2017","journal-title":"Brain Res."},{"key":"10.1016\/j.nsa.2024.104053_bib53","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3109\/03602539808996322","article-title":"Sex-dependent metabolism of xenobiotics","volume":"30","author":"Mugford","year":"1998","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.nsa.2024.104053_bib54","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.5664\/jcsm.6800","article-title":"lemborexant, a dual orexin receptor antagonist (dora) for the treatment of insomnia disorder: results from a bayesian, adaptive, randomized, double-blind, placebo-controlled study","volume":"13","author":"Murphy","year":"2017","journal-title":"J. Clin. Sleep Med."},{"key":"10.1016\/j.nsa.2024.104053_bib55","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1111\/jnc.15328","article-title":"Orexins (hypocretins): the intersection between homeostatic and hedonic feeding","volume":"157","author":"Muthmainah","year":"2021","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nsa.2024.104053_bib56","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/acer.12591","article-title":"Binge-like consumption of ethanol and other salient reinforcers is blocked by orexin-1 receptor inhibition and leads to a reduction of hypothalamic orexin immunoreactivity","volume":"39","author":"Olney","year":"2015","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.nsa.2024.104053_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2018.08.025","article-title":"Therapeutics development for addiction: orexin-1 receptor antagonists","volume":"1731","author":"Perrey","year":"2020","journal-title":"Brain Res."},{"key":"10.1016\/j.nsa.2024.104053_bib58","doi-asserted-by":"crossref","first-page":"9996","DOI":"10.1523\/JNEUROSCI.18-23-09996.1998","article-title":"Neurons containing hypocretin (orexin) project to multiple neuronal systems","volume":"18","author":"Peyron","year":"1998","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nsa.2024.104053_bib59","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/adb.12323","article-title":"Individual differences in orexin-1 receptor modulation of motivation for the opioid remifentanil","volume":"22","author":"Porter-Stransky","year":"2017","journal-title":"Addiction Biol."},{"key":"10.1016\/j.nsa.2024.104053_bib60","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1021\/cn500246j","article-title":"Hypocretin\/Orexin regulation of dopamine signaling and cocaine self- administration is mediated predominantly by hypocretin receptor 1","volume":"6","author":"Prince","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.nsa.2024.104053_bib61","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0092-8674(00)80949-6","article-title":"Orexins and Orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behaviour","volume":"92","author":"Sakurai","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.nsa.2024.104053_bib62","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41398-020-00937-9","article-title":"Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans","volume":"10","author":"Salvadore","year":"2020","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.nsa.2024.104053_bib63","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/BF00181958","article-title":"The alpha 2-adrenoceptor antagonists idazoxan and yohimbine increase rates of DRL responding in rats","volume":"95","author":"Sanger","year":"1988","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.nsa.2024.104053_bib64","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.biopsych.2016.06.010","article-title":"Hypocretin neurotransmission within the central amygdala mediates escalated cocaine self- administration and stress-induced reinstatement in rats","volume":"81","author":"Schmeichel","year":"2017","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.nsa.2024.104053_bib65","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1460-9568.2009.06844.x","article-title":"Orexin\/hypocretin signaling at the orexin 1 receptor regulates cue-elicited cocaine-seeking","volume":"30","author":"Smith","year":"2009","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.nsa.2024.104053_bib66","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/j.1460-9568.2012.08013.x","article-title":"Orexin\/hypocretin 1 receptor antagonist reduces heroin self-administration and cue-induced heroin seeking","volume":"35","author":"Smith","year":"2012","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.nsa.2024.104053_bib67","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/alcalc\/agac012","article-title":"Patterns and correlates of polysubstance use among individuals with severe alcohol use disorder","volume":"57","author":"Stephenson","year":"2022","journal-title":"Alcohol Alcohol"},{"key":"10.1016\/j.nsa.2024.104053_bib68","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1126\/scitranslmed.aao4953","article-title":"Opiates increase the number of hypocretin-producing cells in human and mouse brain and reverse cataplexy in a mouse model of narcolepsy","volume":"10","author":"Thannickal","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.nsa.2024.104053_bib69","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0014-5793(98)01266-6","article-title":"Distribution of orexin receptor mRNA in the rat brain","volume":"438","author":"Trivedi","year":"1998","journal-title":"FEBS Lett."},{"key":"10.1016\/j.nsa.2024.104053_bib70","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3109\/01677063.2011.566953","article-title":"Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist","volume":"25","author":"Winrow","year":"2011","journal-title":"J. Neurogenet."},{"key":"10.1016\/j.nsa.2024.104053_bib71","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1124\/jpet.111.187567","article-title":"Orexin-1 receptor mediation of cocaine seeking in male and female rats","volume":"340","author":"Zhou","year":"2012","journal-title":"J. Pharmacol. Exp. Therapeut."}],"container-title":["Neuroscience Applied"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772408524001182?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772408524001182?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:32:42Z","timestamp":1731630762000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772408524001182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":71,"alternative-id":["S2772408524001182"],"URL":"https:\/\/doi.org\/10.1016\/j.nsa.2024.104053","relation":{},"ISSN":["2772-4085"],"issn-type":[{"value":"2772-4085","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel, non-opioid, selective orexin-1 receptor antagonist for the treatment of substance use disorders","name":"articletitle","label":"Article Title"},{"value":"Neuroscience Applied","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nsa.2024.104053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European College of Neuropsychopharmacology.","name":"copyright","label":"Copyright"}],"article-number":"104053"}}